IVVD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Invivyd Inc (IVVD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong revenue growth, positive news catalysts, and a promising pipeline. Despite short-term risks such as negative net income and insider neutrality, the long-term potential driven by clinical advancements and FDA fast-track designation outweighs the risks.
The technical indicators are moderately bullish. The MACD is positive and expanding, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the RSI is neutral at 60.518. The stock is trading near its resistance level (R1: 1.76), suggesting potential for a breakout.
FDA agreement on late-stage trial design and fast-track status for COVID-19 therapy.
Appointment of a new Chief Medical Officer, Michael Mina, to enhance clinical execution.
Strong revenue growth in Q4 2025 (+24.51% YoY).
DECLARATION Phase 3 trial achieving full enrollment with pivotal data expected mid-
Robust cash position of $226.7 million to fund clinical trials.
Hedge funds are selling, with a 433.14% increase in selling activity over the last quarter.
Net income and EPS have declined significantly (-39.98% and -73.33% YoY, respectively).
Gross margin dropped slightly (-1.47% YoY).
In Q4 2025, revenue increased by 24.51% YoY to $17.2 million, driven by strong product sales. However, net income dropped by 39.98% YoY to -$11.07 million, and EPS fell by 73.33% YoY to -$0.04. The company maintains a strong cash position of $226.7 million, ensuring funding for ongoing clinical trials.
Analysts have shown increasing confidence in the company's future performance, with one upward EPS revision in the past three months. The consensus EPS estimate for FY earnings is -$0.10, reflecting a 93% YoY improvement. Analysts are optimistic about the company's growth trajectory.
